Mesoblast Ltd
rexlemestrocel-L
chronic low back pain
Countdown
450days
Approval decision · ~ Sep 30, 2027 estimated
What's at stake
A final FDA approval decision on rexlemestrocel-L for chronic low back pain is expected ~ Sep 30, 2027.
Primary source
· SEC 6-K
verified 12h ago
“A positive readout will be used in support of an expected regulatory filing in Q3 CY2027 for United States Food and Drug Administration (FDA) approval.”